Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

The purpose of this study is to identify the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized).

• Children and Adults 3 - 30 years of age
• Suspected of having newly diagnosed localized CNS NGGCT
• Must have adequate bone marrow, renal, and liver function

• Induction chemotherapy, the first phase of treatment, which may include carboplatin, etoposide, and ifosfamide
• Magnetic resonance imaging (MRI) scans to check how the tumor responds to induction chemotherapy and decide the next phase of treatment
• Surgery to remove any tumor that remains after induction chemotherapy, if needed
• For participants whose tumors respond well, radiation therapy to the spine and part of the brain
• For participants whose tumors do not respond well, high-dose chemotherapy with thiotepa and a stem cell transplant using your own blood stem cells, followed by radiation therapy to the whole brain and spine
• Medicines to help protect the body during chemotherapy, including drugs that support blood cell recovery (filgrastim or pegfilgrastim) and a drug that protects the bladder (mesna)
• Sample collection for research
• Completing questionnaires